Prelude Therapeutics Inc

PRLD

Prelude Therapeutics Inc

PRLD

Insider Sentiment (TTM):

Last Purchase:2026-04-21Last Sale:-Shares Purchased (TTM):5,630,630Shares Sold (TTM):0

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:30,202,288Shares Outstanding:82,519,981Institutional Ownership Pct.:36.60%

Earnings Market Reaction:

Filing Date:2026-08-11Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	26	22	35	48	26	40	12	11	28	25	25	16
Marketable Securities Current	125	60	68	7	47	59	121	142	152	177	208	215
Prepaid Expense And Other Assets Current	3	3	2	3	4	3	2	3	3	3	3	4
Assets Current	155	85	106	58	77	102	136	156	183	205	236	235
Restricted Cash	3	3	3	3	4	4	4	4	4	4	4	4
Property Plant And Equipment Net	4	5	5	6	6	6	7	7	8	7	7	7
Operating Lease Right Of Use Asset	26	27	27	28	28	28	29	29	30	30	30	0
Other Assets	-	-	-	0	0	0	-	0	0	0	-	-
Prepaid Expense And Other Assets Noncurrent	0	0	0	-	-	-	0	-	-	-	0	12
Assets	189	120	141	95	115	141	176	197	224	247	278	259
Liabilities And Stockhold…
Liabilities Current
Accounts Payable Current	2	2	4	3	5	6	8	6	6	5	5	5
Accrued Liabilities Current	8	6	13	13	13	11	15	14	11	10	16	11
Deferred Revenue Current	25	31	34	-	-	-	0	-	3	-	-	-
Operating Lease Liability Current	3	3	3	3	3	3	2	2	2	2	1	0
Finance Lease Liability Current	-	-	0	0	0	0	0	0	1	-	-	-
Liabilities Current	38	42	53	18	21	20	26	22	23	18	22	17
Deferred Revenue Noncurrent	0	0	2	-	-	-	0	-	-	-	-	-
Other Liabilities Noncurrent	3	3	3	3	3	3	3	3	3	3	3	3
Operating Lease Liability Noncurrent	15	15	15	15	15	15	15	15	15	15	15	-
Liabilities	56	59	73	36	39	38	44	41	42	36	41	20
Stockholders Equity
Additional Paid In Capital Common Stock	841	754	752	725	723	719	715	711	705	699	693	662
Accumulated Other Comprehensive Income Loss Net Of…	-0	-0	0	0	-0	0	0	0	-0	-0	0	-1
Retained Earnings Accumulated Deficit	-707	-693	-683	-667	-647	-616	-584	-555	-523	-488	-456	-423
Stockholders Equity	134	60	69	59	76	103	131	156	182	211	237	238
Liabilities And Stockholders Equity	189	120	141	95	115	141	176	197	224	247	278	259
Voting Common Stock	-	0	48	0	-44	44	13	0	29	13	0	13
Nonvoting Common Stock	-	0	0	0	-13	13	13	0	0	13	13	13

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	-17.89%	5.82%	8.84%	-	-	-	-	-	-	-	-	-
2025	11.31%	-1.38%	16.83%	30.16%	55.56%	68.25%	-0.68%	85.71%	25.85%	-3.89%	30.56%	8.89%
2024	4.05%	2.97%	56.49%	2.11%	-57.89%	-73.89%	-20.45%	1.52%	-7.95%	0.75%	32.39%	32.24%
2023	-	-	-	-	-	-	79.03%	126.34%	74.73%	27.01%	35.06%	10.92%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	4.07	2.03	1.99	3.21	3.68	5.18	5.30	7.04	7.83	11.64	10.79	13.91
Quick Ratio	3.99	1.95	1.95	3.02	3.50	5.01	5.21	6.91	7.71	11.44	10.67	13.65
Working Capital	116.86M	42.87M	52.70M	40.14M	55.97M	82.62M	110.25M	134.16M	159.38M	187.72M	213.76M	218.02M
Leverage & Debt
Debt to Equity	0.42	0.99	1.06	0.62	0.52	0.37	0.34	0.26	0.23	0.17	0.17	0.09
Debt Ratio	0.29	0.50	0.51	0.38	0.34	0.27	0.25	0.21	0.19	0.15	0.15	0.08
Efficiency & Turnover
Asset Turnover TTM	0.15	0.13	0.08	0.07	0.04	0.04	0.03	0.01	0.00	0.00	0.00	0.00
Per Share Metrics
Diluted EPS TTM	-0.61	-0.94	-1.29	-1.47	-1.64	-1.68	-1.68	-1.73	-1.71	-1.66	-2.02	-1.74
Free Cash Flow Per Share TTM	-0.47	-0.53	-0.73	-0.87	-0.98	-1.39	-1.37	-1.42	-1.41	-1.48	-1.83	-1.61
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Operating Profit Margin TTM	-300.56%	-503.21%	-861.33%	-1,152.85%	-1,928.67%	-1,999.67%	-1,995.91%	-4,775.40%	-	-	-	-
Net Profit Margin TTM	-269.75%	-465.30%	-819.59%	-1,064.50%	-1,775.97%	-1,826.10%	-1,816.76%	-4,383.90%	-	-	-	-
Growth Metrics
Net Revenue Growth (1Y)	220.34%	138.86%	73.43%	250.00%	-	-	-	-	-	-	-	-
Net Income Growth (1Y)	-51.34%	-39.14%	-21.76%	-15.01%	-4.26%	1.82%	4.38%	12.03%	11.23%	10.43%	5.54%	-1.87%
EPS Growth (1Y)	-62.42%	-43.96%	-22.93%	-15.32%	-4.56%	1.48%	-16.89%	-0.11%	-17.43%	-30.40%	-17.17%	-31.16%
Valuation Metrics
P/E TTM	-8.67	-3.63	-2.24	-0.98	-0.49	-0.46	-0.76	-1.19	-2.22	-2.86	-2.12	-1.78
P/B TTM	3.92	4.69	3.25	1.87	0.81	0.57	0.74	1.00	1.58	1.70	1.09	0.88
P/S TTM	23.39	16.88	18.38	10.44	8.78	8.34	13.81	52.34	-	-	-	-
Market Cap	524.41M	282.22M	223.17M	109.63M	61.48M	58.36M	96.65M	157.02M	288.65M	358.99M	257.72M	209.01M
Enterprise Value	498.08M	260.46M	187.92M	62.10M	35.73M	18.14M	84.39M	146.25M	261.33M	334.28M	232.43M	193.11M
Calculated Values
Free Cash Flow TTM	-45.85M	-43.83M	-56.42M	-66.06M	-74.31M	-105.85M	-103.65M	-107.56M	-106.48M	-111.71M	-110.58M	-109.19M
Net Debt	-26.33M	-21.76M	-35.26M	-47.53M	-25.75M	-40.22M	-12.27M	-10.78M	-27.32M	-24.71M	-25.29M	-15.90M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
PEG Ratio
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
EV Revenue TTM
EV FCF TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-04-21Purchase

Owner: Orbimed, Genesis Gp Llc, …

Title: -

Shares: 2,815,315

Price/Share: $4.44

Value: $12,499,998.60

Shares Owned: 11,808,945

Relationship: Director,TenPercentOwner

Ownership: Indirect

2026-04-21Purchase

Owner: Bonita, David P

Title: -

Shares: 2,815,315

Price/Share: $4.44

Value: $12,499,998.60

Shares Owned: 11,808,945

Relationship: Director,TenPercentOwner

Ownership: Indirect

2025-03-25Purchase

Owner: Combs, Andrew

Title: Chief Chemistry Officer

Shares: 100,000

Price/Share: $0.69

Value: $69,000.00

Shares Owned: 480,123

Relationship: Officer

Ownership: Direct

2025-03-25Purchase

Owner: Vaddi, Krishna

Title: CEO

Shares: 675,000

Price/Share: $0.69

Value: $465,750.00

Shares Owned: 1,999,296

Relationship: Director,Officer

Ownership: Direct

2025-03-21Purchase

Owner: Vaddi, Krishna

Title: CEO

Shares: 15,000

Price/Share: $0.73

Value: $10,950.00

Shares Owned: 1,324,296

Relationship: Director,Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-04-21	Orbimed, Genesis Gp Llc, …	Director,TenPercentOwner	-	Indirect	Purchase	2,815,315	4.44	$12,499,998.60	11,808,945	4
2026-04-21	Bonita, David P	Director,TenPercentOwner	-	Indirect	Purchase	2,815,315	4.44	$12,499,998.60	11,808,945	4
2025-03-25	Combs, Andrew	Officer	Chief Chemistry Officer	Direct	Purchase	100,000	0.69	$69,000.00	480,123	4
2025-03-25	Vaddi, Krishna	Director,Officer	CEO	Direct	Purchase	675,000	0.69	$465,750.00	1,999,296	4
2025-03-21	Vaddi, Krishna	Director,Officer	CEO	Direct	Purchase	15,000	0.73	$10,950.00	1,324,296	4
2025-03-17	Vaddi, Krishna	Director,Officer	CEO	Direct	Purchase	9,106	0.75	$6,829.50	1,303,880	4
2025-03-13	Vaddi, Krishna	Director,Officer	CEO	Direct	Purchase	50,000	0.72	$36,000.00	1,264,775	4
2024-12-31	Vaddi, Krishna	Director,Officer	CEO	Indirect	Purchase	5,000	1.21	$6,050.00	142,553	4
2024-12-30	Vaddi, Krishna	Director,Officer	CEO	Indirect	Purchase	10,000	1.20	$12,000.00	137,553	4
2024-12-23	Combs, Andrew	Officer	Chief Chemistry Officer	Direct	Purchase	60,000	1.37	$82,200.00	377,623	4
2024-12-19	Lim, Bryant David	Officer	CLO, Interim CFO, Corp Sec.	Direct	Purchase	25,000	0.91	$22,750.00	27,400	4
2024-12-19	Vaddi, Krishna	Director,Officer	CEO	Indirect	Purchase	6,888	0.89	$6,130.32	127,553	4
2023-05-25	Vaddi, Krishna	Director,Officer	CEO	Direct	Purchase	900	5.31	$4,779.00	1,067,275	4
2023-05-24	Lim, Bryant David	Officer	Chief Legal Officer, Corp Sec.	Direct	Purchase	2,400	5.39	$12,936.00	2,400	4
2023-05-23	Vaddi, Krishna	Director,Officer	CEO	Direct	Purchase	11,856	5.63	$66,749.28	1,065,375	4
2023-05-23	Chardonnet, Laurent	Officer	Chief Financial Officer	Direct	Purchase	5,000	5.50	$27,500.00	42,165	4
2023-05-22	Orbimed, Capital Llc, Orb…	Director,TenPercentOwner	-	Indirect	Purchase	869,565	5.75	$4,999,998.75	10,119,756	4
2023-05-22	Bonita, David P	Director,TenPercentOwner	-	Indirect	Purchase	869,565	5.75	$4,999,998.75	10,119,756	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

36.60%

Inst. Shares: 30,202,288

Shares Outstanding: 82,519,981

2025-12-31

35.30%

Inst. Shares: 27,167,192

Shares Outstanding: 76,956,194

2025-09-30

33.69%

Inst. Shares: 25,652,773

Shares Outstanding: 76,132,337

2025-06-30

33.74%

Inst. Shares: 25,636,961

Shares Outstanding: 75,993,941

2025-03-31

37.76%

Inst. Shares: 28,692,388

Shares Outstanding: 75,986,281

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	30,202,288	82,519,981	36.60%
2025-12-31	27,167,192	76,956,194	35.30%
2025-09-30	25,652,773	76,132,337	33.69%
2025-06-30	25,636,961	75,993,941	33.74%
2025-03-31	28,692,388	75,986,281	37.76%
2024-12-31	30,598,241	75,805,840	40.36%
2024-09-30	33,341,698	75,855,949	43.95%
2024-06-30	32,970,978	75,762,152	43.52%
2024-03-31	32,963,660	75,735,954	43.52%
2023-12-31	33,373,725	60,357,052	55.29%
2023-09-30	35,296,186	67,639,993	52.18%
2023-06-30	34,690,341	56,240,491	61.68%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

Prelude Therapeutics Inc (PRLD) — SEC Financial Statements & Analysis

Prelude Therapeutics Inc (PRLD) is a pharmaceutical preparations company, incorporated in DE. Prelude Therapeutics Inc trades on Nasdaq as: PRLD. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), Prelude Therapeutics Inc reported a 220.34% year-over-year revenue growth, a Debt-to-Equity ratio of 0.42x, a Price-to-Sales (P/S) ratio of 23.39x (TTM), a Price-to-Book (P/B) ratio of 3.92x (TTM), at a market cap of $524.41M. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: 220.34%
Debt To Equity: 0.42x
P/S TTM: 23.39x
P/B TTM: 3.92x
Market Cap: $524.41M

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Prelude Therapeutics Inc in?

Prelude Therapeutics Inc (PRLD) operates in the Pharmaceutical Preparations industry.

What is PRLD's market cap?

Prelude Therapeutics Inc (PRLD) has a market capitalization of $524.41M as of 2026-06-30.

What exchange does PRLD trade on?

Prelude Therapeutics Inc (PRLD) trades on the Nasdaq.

Where is Prelude Therapeutics Inc incorporated?

Prelude Therapeutics Inc is incorporated in DE.